Actively Recruiting

Phase Not Applicable
Age: 0Days - 3Months
All Genders
NCT06374147

"Prapela® SVS Incubator Pad for Apnea of Prematurity

Led by Tufts Medical Center · Updated on 2025-03-07

140

Participants Needed

2

Research Sites

99 weeks

Total Duration

On this page

Sponsors

T

Tufts Medical Center

Lead Sponsor

U

University of Alabama at Birmingham

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study proposes to complete the development of and then establish the safety, efficacy, and clinical risk/benefit of a novel hospital incubator pad with stochastic vibrotactile stimulation (SVS) that will provide a complementary treatment and the first improvement in the clinical management of apnea of prematurity (AOP) in over 20 years. Currently, the only approved therapy for AOP is Caffeine Citrate. The SVS mattress pad can prove to be an effective, non-invasive adjunct to Caffeine Citrate for preterm infants with potential to shorten the need for respiratory support as well as overall shortened length of stay.

CONDITIONS

Official Title

"Prapela® SVS Incubator Pad for Apnea of Prematurity

Who Can Participate

Age: 0Days - 3Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Gestational age between 22 weeks 0 days and 32 weeks 6 days
  • Either sex
  • Single birth
  • At least 4 clinically documented apnea events in the previous 24 hours
  • Receiving caffeine citrate at a dose of at least 5 mg/kg/day, with or without respiratory support (oxygen, nasal cannula, or CPAP without added rate or pressure support) as needed by clinical team
Not Eligible

You will not qualify if you...

  • Intubation and mechanical ventilation
  • Use of non-invasive positive pressure ventilation (NIPPV) if not intubated
  • Use of pressure support breaths while on CPAP
  • Refusal or withdrawal of consent
  • Major congenital malformations (except patent ductus arteriosus or small hernia)
  • Known breathing disorders other than apnea of prematurity (e.g., congenital central hypoventilation syndrome, laryngotracheomalacia)
  • Caffeine citrate dosing exceeding FDA recommended dose in the first 24 hours if deemed necessary by clinical team

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

University of Alabama

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Tufts Medical Center

Boston, Massachusetts, United States, 02111

Actively Recruiting

Loading map...

Research Team

R

Rachana Singh, MD, MS

CONTACT

J

John Konsin

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here